Teva Pharmaceutical Faces Revenue and Profitability Declines Ahead of Q1 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy TEVA?
Source: NASDAQ.COM
- Revenue and Profit Outlook: Analysts expect Teva's Q1 revenue to be $3.79 billion, nearly 3% lower than the same period in 2025, with a projected 12% decline in earnings per share (EPS) to $0.46, indicating challenges during the company's transformation.
- Strategic Transformation Progress: Announced in 2023, Teva's 'Pivot to Growth' strategy has seen some proprietary drug sales increase, yet the company still relies on generics and biosimilars for 54% of its revenue, highlighting competitive pressures in the market.
- Future Potential: Despite short-term performance concerns, analysts forecast a revenue rebound to $17.2 billion in 2027, a 4% increase, with EPS expected to rise 17% to $3.13, suggesting significant value in the company's R&D pipeline.
- Market Reaction Strategy: Ahead of the earnings release, investors are advised to proceed cautiously, potentially waiting for a post-earnings dip to buy in, capitalizing on Teva's future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 30.640
Low
29.00
Averages
35.71
High
40.00
Current: 30.640
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teva Pharmaceutical's Q1 Results Preview and Strategic Growth Insights
- Strategic Transformation Success: Teva formally announced its 'Pivot to Growth' strategy in 2023, focusing on proprietary drug development, successfully launching the blockbuster Austedo with annual sales exceeding $2 billion, indicating its potential to regain growth in a competitive market.
- Innovative Drug Sales Growth: Austedo's global sales surged 34% year-over-year in 2025 to nearly $2.3 billion, while migraine treatment Ajovy and psychiatric drug Uzedy saw sales increases of 3% and 63%, respectively, demonstrating growing market acceptance of Teva's innovative products.
- Stable Revenue Structure: Despite a modest 4% revenue growth to $17.3 billion in 2025, Teva's generics and biosimilars accounted for 54% of total revenue, showcasing the company's stability and resilience in traditional markets amidst rising competition.
- Optimistic Future Outlook: Analysts project Teva's revenue to rebound to $17.2 billion in 2027, a 4% increase, with earnings per share expected to rise 17% to $3.13, reflecting confidence in the company's future drug development potential and market positioning.
See More
Teva Pharmaceutical Faces Revenue and Profitability Declines Ahead of Q1 Results
- Revenue and Profit Outlook: Analysts expect Teva's Q1 revenue to be $3.79 billion, nearly 3% lower than the same period in 2025, with a projected 12% decline in earnings per share (EPS) to $0.46, indicating challenges during the company's transformation.
- Strategic Transformation Progress: Announced in 2023, Teva's 'Pivot to Growth' strategy has seen some proprietary drug sales increase, yet the company still relies on generics and biosimilars for 54% of its revenue, highlighting competitive pressures in the market.
- Future Potential: Despite short-term performance concerns, analysts forecast a revenue rebound to $17.2 billion in 2027, a 4% increase, with EPS expected to rise 17% to $3.13, suggesting significant value in the company's R&D pipeline.
- Market Reaction Strategy: Ahead of the earnings release, investors are advised to proceed cautiously, potentially waiting for a post-earnings dip to buy in, capitalizing on Teva's future growth potential.
See More
Teva Pharmaceutical Featured in Einhorn's Top Stock Picks
- Stake Increase: Teva Pharmaceutical has been part of Greenlight Capital's 13F portfolio since Q4 2023, starting with 268,000 shares, and has seen steady increases of 21%, 44%, and 21% in subsequent quarters.
- Massive Buying Activity: In Q2 2025, Greenlight Capital increased its stake by over 550%, reflecting strong confidence in Teva, although by Q4 2025, holdings slightly decreased to just over 3 million shares, down nearly 20% from Q3.
- Innovative Drug Sales: Teva's innovative brands, including AUSTEDO, collectively surpassed $1 billion in sales for the first time in Q4 2025, with projections indicating sales could reach $2.5 billion by 2027, showcasing the company's successful shift towards high-margin brand drugs.
- R&D Investment: Teva is developing a promising blockbuster for inflammatory bowel disease, with recent data positioning it as a best-in-class therapy, and a $400 million funding agreement with Blackstone will accelerate its development, further attracting institutional interest.
See More
Teva's FDA Approval of Long-Acting Drug Could Be Major Catalyst
- New Drug Approval Outlook: Teva's New Drug Application for long-acting schizophrenia drug olanzapine has been accepted by the FDA, and if approved, it is expected to significantly enhance patient adherence, driving sales growth and becoming the company's most meaningful catalyst.
- Specialty Drug Sales Surge: Teva's Austedo generated $2.26 billion in sales in 2025, marking a 34% year-over-year increase, with expectations to reach between $2.4 billion and $2.55 billion in 2026, showcasing strong momentum in the specialty drug sector.
- Biosimilar Market Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, potentially competing with Amgen and Johnson & Johnson, which will further solidify its position as the second-largest player in the biosimilar market.
- Investor Confidence Boost: Analysts are optimistic about Teva's future, with 12 out of 15 analysts rating the stock as a
See More
Teva Pharmaceutical Shares Surge 130% with Optimistic Outlook
- FDA Approval Catalyst: Teva's long-acting olanzapine injectable suspension NDA has been accepted by the FDA, with a decision expected later this year; approval could significantly enhance patient adherence, with combined annual sales with Uzedy projected to exceed $2 billion.
- Specialty Drug Sales Surge: Teva's specialty drug Austedo generated $2.26 billion in sales in 2025, a 34% year-over-year increase, with expectations for 2026 sales to rise between $2.4 billion and $2.55 billion, reflecting strong market demand and competitive positioning in the specialty drug sector.
- Biosimilar Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, further solidifying its position as the second-largest player in the biosimilar market, with anticipated competition against giants like Amgen and Johnson & Johnson, driving future revenue growth.
- Market Risk Factors: Despite several catalysts propelling stock price growth, a market crash or significant pipeline issues could derail Teva's momentum; however, the company's pipeline is relatively de-risked, and with a forward P/E of only 11.7, it presents a compelling value investment opportunity.
See More
Greenlight Capital Achieves 6.5% Return in Q1 Amid Market Decline
- Investment Performance: David Einhorn's Greenlight Capital funds achieved a 6.5% return in Q1, significantly outperforming the S&P 500 index's 4.4% decline, demonstrating the effectiveness of its investment strategy and market adaptability.
- Winners and Losers: In this quarter, gold, Acadia Healthcare (ACHC), DHT Holdings (DHT), and Core Natural Resources (CNR) emerged as major winners, while SOFR futures, Kyndryl (KD), and Graphic Packaging (GPK) were the biggest losers, reflecting market volatility and sector performance disparities.
- Quantitative Ratings Analysis: In the aQuant ratings snapshot of core holdings, DHT Holdings (DHT) received a
See More
Teva Pharmaceutical's Q1 Results Preview and Strategic Growth Insights
- Strategic Transformation Success: Teva formally announced its 'Pivot to Growth' strategy in 2023, focusing on proprietary drug development, successfully launching the blockbuster Austedo with annual sales exceeding $2 billion, indicating its potential to regain growth in a competitive market.
- Innovative Drug Sales Growth: Austedo's global sales surged 34% year-over-year in 2025 to nearly $2.3 billion, while migraine treatment Ajovy and psychiatric drug Uzedy saw sales increases of 3% and 63%, respectively, demonstrating growing market acceptance of Teva's innovative products.
- Stable Revenue Structure: Despite a modest 4% revenue growth to $17.3 billion in 2025, Teva's generics and biosimilars accounted for 54% of total revenue, showcasing the company's stability and resilience in traditional markets amidst rising competition.
- Optimistic Future Outlook: Analysts project Teva's revenue to rebound to $17.2 billion in 2027, a 4% increase, with earnings per share expected to rise 17% to $3.13, reflecting confidence in the company's future drug development potential and market positioning.
See More
Teva Pharmaceutical Faces Revenue and Profitability Declines Ahead of Q1 Results
- Revenue and Profit Outlook: Analysts expect Teva's Q1 revenue to be $3.79 billion, nearly 3% lower than the same period in 2025, with a projected 12% decline in earnings per share (EPS) to $0.46, indicating challenges during the company's transformation.
- Strategic Transformation Progress: Announced in 2023, Teva's 'Pivot to Growth' strategy has seen some proprietary drug sales increase, yet the company still relies on generics and biosimilars for 54% of its revenue, highlighting competitive pressures in the market.
- Future Potential: Despite short-term performance concerns, analysts forecast a revenue rebound to $17.2 billion in 2027, a 4% increase, with EPS expected to rise 17% to $3.13, suggesting significant value in the company's R&D pipeline.
- Market Reaction Strategy: Ahead of the earnings release, investors are advised to proceed cautiously, potentially waiting for a post-earnings dip to buy in, capitalizing on Teva's future growth potential.
See More
Teva Pharmaceutical Featured in Einhorn's Top Stock Picks
- Stake Increase: Teva Pharmaceutical has been part of Greenlight Capital's 13F portfolio since Q4 2023, starting with 268,000 shares, and has seen steady increases of 21%, 44%, and 21% in subsequent quarters.
- Massive Buying Activity: In Q2 2025, Greenlight Capital increased its stake by over 550%, reflecting strong confidence in Teva, although by Q4 2025, holdings slightly decreased to just over 3 million shares, down nearly 20% from Q3.
- Innovative Drug Sales: Teva's innovative brands, including AUSTEDO, collectively surpassed $1 billion in sales for the first time in Q4 2025, with projections indicating sales could reach $2.5 billion by 2027, showcasing the company's successful shift towards high-margin brand drugs.
- R&D Investment: Teva is developing a promising blockbuster for inflammatory bowel disease, with recent data positioning it as a best-in-class therapy, and a $400 million funding agreement with Blackstone will accelerate its development, further attracting institutional interest.
See More
Teva's FDA Approval of Long-Acting Drug Could Be Major Catalyst
- New Drug Approval Outlook: Teva's New Drug Application for long-acting schizophrenia drug olanzapine has been accepted by the FDA, and if approved, it is expected to significantly enhance patient adherence, driving sales growth and becoming the company's most meaningful catalyst.
- Specialty Drug Sales Surge: Teva's Austedo generated $2.26 billion in sales in 2025, marking a 34% year-over-year increase, with expectations to reach between $2.4 billion and $2.55 billion in 2026, showcasing strong momentum in the specialty drug sector.
- Biosimilar Market Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, potentially competing with Amgen and Johnson & Johnson, which will further solidify its position as the second-largest player in the biosimilar market.
- Investor Confidence Boost: Analysts are optimistic about Teva's future, with 12 out of 15 analysts rating the stock as a
See More
Teva Pharmaceutical Shares Surge 130% with Optimistic Outlook
- FDA Approval Catalyst: Teva's long-acting olanzapine injectable suspension NDA has been accepted by the FDA, with a decision expected later this year; approval could significantly enhance patient adherence, with combined annual sales with Uzedy projected to exceed $2 billion.
- Specialty Drug Sales Surge: Teva's specialty drug Austedo generated $2.26 billion in sales in 2025, a 34% year-over-year increase, with expectations for 2026 sales to rise between $2.4 billion and $2.55 billion, reflecting strong market demand and competitive positioning in the specialty drug sector.
- Biosimilar Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, further solidifying its position as the second-largest player in the biosimilar market, with anticipated competition against giants like Amgen and Johnson & Johnson, driving future revenue growth.
- Market Risk Factors: Despite several catalysts propelling stock price growth, a market crash or significant pipeline issues could derail Teva's momentum; however, the company's pipeline is relatively de-risked, and with a forward P/E of only 11.7, it presents a compelling value investment opportunity.
See More
Greenlight Capital Achieves 6.5% Return in Q1 Amid Market Decline
- Investment Performance: David Einhorn's Greenlight Capital funds achieved a 6.5% return in Q1, significantly outperforming the S&P 500 index's 4.4% decline, demonstrating the effectiveness of its investment strategy and market adaptability.
- Winners and Losers: In this quarter, gold, Acadia Healthcare (ACHC), DHT Holdings (DHT), and Core Natural Resources (CNR) emerged as major winners, while SOFR futures, Kyndryl (KD), and Graphic Packaging (GPK) were the biggest losers, reflecting market volatility and sector performance disparities.
- Quantitative Ratings Analysis: In the aQuant ratings snapshot of core holdings, DHT Holdings (DHT) received a
See More
